A series of oral VEGFR TKIs have now been approved for the treatment of RCC, including sorafenib (Nexavar®, Bayer), sunitinib (Sutent®, Pfizer), pazopanib (Votrient®, Novartis), axitinib (Inlyta®, Pfizer), cabozantinib (Cabometyx®, Exelixis), lenvatinib (Lenvima®, Eisai), and tivozanib (Fotivda®, Aveo). Here, KDR is linked to renal cell carcinoma.